Teosyal PureSense Redensity 1 2x1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Teosyal® PureSense Redensity 1 is Teoxane's skin redensifier and the only injectable product of the Teosyal range that is not cross-linked: 15 mg/ml of hyaluronic acid of non-animal origin with an average molecular weight above 1 million daltons, formulated in a phosphate buffer supplemented with 8 amino acids, 3 antioxidants, vitamin B6 and 2 minerals. It provides no volume: it acts on the quality, hydration and elasticity of the skin.
- HA 15 mg/ml, non-cross-linked
- Molecular weight > 1 million daltons
- Lidocaine 0.3 % (3 mg/ml)
- Contents 2 syringes × 1 ml
- Needles 4 × 30G ½"
- Protocol 2–3 sessions + maintenance
Composition and technology
- Non-cross-linked hyaluronic acid: 15 mg/ml, of non-animal origin, with an average molecular weight above 1 million daltons. As it is not cross-linked, it contains no BDDE.
- Lidocaine hydrochloride: 0.3 % by mass (3 mg/ml).
- Dermo-restructuring complex (supplemented phosphate buffer, pH 7.3): the buffer is not inert, it incorporates the following active components:
- 3 antioxidants: α-lipoic acid, glutathione and N-acetyl-L-cysteine.
- 8 amino acids: L-arginine, L-isoleucine, L-leucine, L-lysine monohydrate, glycine, L-valine, L-threonine and L-proline — precursors for collagen and elastin synthesis.
- 1 vitamin: pyridoxine (vitamin B6) in the form of the hydrochloride.
- 2 minerals: zinc acetate dihydrate and copper sulphate pentahydrate, enzyme cofactors.
- Sodium chloride.
- Behaviour of the gel: owing to its marked fluidity and its viscoelastic properties it distributes homogeneously within the tissue, which ensures an optimal level of hydration and a lasting improvement of skin texture and elasticity.
Position within the Teosyal PureSense range
| Redensity 1 (this product) | Non-cross-linked HA 15 mg/ml + dermo-restructuring complex · 1 ml · 30G ½" — skin quality and hydration · ≥ 3 months |
|---|---|
| Redensity 2 | HA 15 mg/ml (cross-linking < 10 %) + dermo-restructuring complex · 1 ml · 30G ½" — periorbital region and tear trough · ≥ 12 months |
| Global Action | HA 25 mg/ml · 1 ml — wrinkles and skin depressions, lips · 12–18 months |
| Deep Lines | HA 25 mg/ml · 1 ml — marked wrinkles and depressions · 12–18 months |
| Kiss | HA 25 mg/ml (cross-linking < 10 %) · 1 ml · 27G ½" — lips and perioral region · 12–18 months |
| Ultra Deep | HA 25 mg/ml (cross-linking < 10 %) · 1.2 ml · 25G 1" — facial volume and contour · 15–18 months |
| Ultimate | HA 22 mg/ml · 1 ml — facial contour · 15–18 months |
The cross-linked PureSense range declares a degree of cross-linking below 10 % (NMR), compared with the < 5 % of the RHA range. It is a firmer gel with a greater capacity for projection at an equal concentration; the RHA range instead prioritises adaptation to movement in areas of high facial animation. Redensity 1 falls outside this logic: it is not cross-linked and provides no volume.
Indications and treatment areas
Improvement of skin quality and hydration and correction of dull skin with signs of ageing, as well as prevention of superficial fine wrinkles.
- Face
- Neck
- Décolleté
Redensity 1 is not a volumising filler. Where the objective is to correct a fold or to restore volume, the cross-linked references of the range are the appropriate choice.
Technique and treatment protocol
- Injection plane: intradermal or subcutaneous.
- Needles included: 30G ½", two per syringe (4 per pack).
- Cannula: as an alternative to the needle, a 25G or 27G blunt cannula may be used; the manufacturer has verified compatibility with TSK 25G/50 mm and TSK 27G/38 mm.
- Protocol: 2 to 3 sessions at an interval of 3 or 4 weeks, followed by a maintenance session 2 or 3 times a year.
- Maximum volume: 6 ml per session.
- Estimated duration: at least 3 months — hence the schedule of repeated sessions compared with the single session of a cross-linked filler.
- Do not inject into the epidermis. Do not combine in the same session with peeling, laser or ultrasound.
Technical data
| Manufacturer | Teoxane SA (Laboratoires Teoxane), Geneva, Switzerland |
|---|---|
| Active substance | Non-cross-linked hyaluronic acid 15 mg/ml |
| Origin of the HA | Non-animal, average molecular weight > 1 million daltons |
| Cross-linking | None — non-cross-linked product, without BDDE |
| Anaesthetic | Lidocaine HCl 0.3 % by mass |
| Associated complex | 8 amino acids, 3 antioxidants, vitamin B6, zinc and copper |
| pH | 7.3 (supplemented phosphate buffer) |
| Presentation | 2 pre-filled syringes of 1 ml |
| Needles | 4 × 30G ½" (2 per syringe) |
| Compatible cannula | 25G (TSK 25G/50 mm) or 27G (TSK 27G/38 mm) |
| Treatment plane | Intradermal or subcutaneous |
| Estimated duration | At least 3 months |
| Classification | CE-marked medical device |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: between 2 °C and 25 °C, protected from direct sunlight.
- Do not use after the expiry date stated on the pack.
- Sterile single-use product. Do not reuse or re-sterilise the syringe or the needles.
- The pack contains: 2 pre-filled syringes of 1 ml, 4 sterile 30G ½" needles, and two traceability labels per syringe — one to be given to the patient and one for the medical record.
Contraindications and warnings
Contraindications: skin disorders, inflammation or infection in or near the treatment area; allergy to hyaluronic acid and a history of severe allergy or anaphylactic shock; allergy to lidocaine or to amide-type local anaesthetics; recent peel, laser or ultrasound treatment; autoimmune diseases; heart disease or treatment with beta-blockers; hepatocellular insufficiency or treatment for liver disease; epilepsy; porphyria; pregnancy, breastfeeding and patients under 18 years of age.
Vascular warning: intravascular injection may cause vascular occlusion, ischaemia and necrosis of the treated area. In the most serious cases it may lead to visual disturbances or blindness and to cerebral ischaemia or haemorrhage. Never inject intravascularly.
Before injection: do not treat if a dental procedure has been performed in the previous 15 days; avoid aspirin, anti-inflammatory drugs, anticoagulants and vitamin E during the preceding week; avoid alcohol and intense sun exposure on the previous day and on the day itself; remove make-up completely.
After injection: during the first 12 hours, do not apply make-up or undertake intense exertion; during the following week, avoid alcohol, prolonged sun or UV exposure, temperatures below 0 °C, sauna and hammam; for 15 days, do not undergo dental procedures or other aesthetic treatments.
Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the official documentation of Teoxane SA (instructions for use TEOSYAL® PureSense REDENSITY 1, ref. 230586-00, and patient product information). This information sheet does not replace the instructions for use supplied with the product.